A study finds 1 year of avelumab treatment improves distant disease free and overall survival rates in patients with early ...

Patients with resectable stage 3 melanoma should talk about pretreatment therapy with their cancer care teams, an expert said ...

Immunotherapy before surgery for patients with metastatic melanoma appears to be especially successful. Fifty-nine percent of ...

Long-term data from the IMpower010 trial (NCT02486718) continues to support the use of atezolizumab (Tecentriq) as an ...

Two courses of neoadjuvant ipilimumab/nivolumab highly improve event free survival (EFS) in patients with macroscopic stage 3 ...

Armaghani, MD, highlights two key presentations. First, a retrospective study on adjuvant endocrine therapy in ER-low breast ...

There was no significant difference in metastasis-free survival between the ADT and non-ADT groups over 10 years. 2. Adverse ...

Neoadjuvant (primary cancer treatment) Opdivo (nivolumab) plus Yervoy (ipilimumab) followed by therapeutic lymph node ...

These data from the COMBI-AD trial represent the longest follow-up to date of adjuvant treatment for stage III melanoma.

Agricultural Activator Adjuvant Market set to hit worth US$ 6.6 billion at CAGR 4.9% during forecast period 2024 to 2034 ...

The global agricultural adjuvant market is projected to grow at a compound annual growth rate (CAGR) of 6% from 2024 to 2034, ...